Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

ANGPT2 (Angiopoietin 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

ANGPT2 elevation	Hepatocellular Cancer	ANGPT2 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
ANGPT2 elevation	Hepatocellular Cancer	ANGPT2 elevation	Hepatocellular Cancer	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
ANGPT2-L	Hepatocellular Cancer	ANGPT2-L	Hepatocellular Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
ANGPT2 expression	Renal Cell Carcinoma	ANGPT2 expression	Renal Cell Carcinoma	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
ANGPT2-L	Hepatocellular Cancer	ANGPT2-L	Hepatocellular Cancer	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
ANGPT2 elevation	Colorectal Cancer	ANGPT2 elevation	Colorectal Cancer	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3
ANGPT2-L	Pancreatic Ductal Adenocarcinoma	ANGPT2-L	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
ANGPT2-L	Pancreatic Ductal Adenocarcinoma	ANGPT2-L	Pancreatic Ductal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3